PMID- 38347279
OWN - NLM
STAT- MEDLINE
DCOM- 20240214
LR  - 20240324
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 150
IP  - 2
DP  - 2024 Feb 12
TI  - Clinical characteristics of patients treated with immune checkpoint inhibitors in 
      EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational 
      registry study.
PG  - 89
LID - 10.1007/s00432-024-05618-4 [doi]
LID - 89
AB  - PURPOSE: Immune checkpoint inhibitors (ICIs) are ineffective against epidermal 
      growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This 
      study aimed to investigate the clinical characteristics of patients who were 
      treated or not treated with ICIs, and of those who benefit from immunotherapy in 
      EGFR-mutant NSCLC. METHODS: We analyzed patients with unresectable stage III/IV 
      or recurrent NSCLC harboring EGFR mutations using a prospective umbrella-type 
      lung cancer registry (CS-Lung-003). RESULTS: A total of 303 patients who met the 
      eligibility criteria were analyzed. The median age was 69 years; 116 patients 
      were male, 289 had adenocarcinoma, 273 had major mutations, and 67 were treated 
      with ICIs. The duration of EGFR-TKI treatment was longer in the Non-ICI group 
      than in the ICI group (17.1 vs. 12.7 months, p < 0.001). Patients who received 
      ICIs for more than 6 months were categorized into the durable clinical benefit 
      (DCB) group (24 patients), and those who received ICIs for less than 6 months 
      into the Non-DCB group (43 patients). The overall survival in the DCB group 
      exhibited longer than the Non-DCB group (69.3 vs. 47.1 months), and an equivalent 
      compared to that in the Non-ICI group (69.3 vs. 68.9 months). Multivariate 
      analysis for time to next treatment (TTNT) of ICIs showed that a poor PS was 
      associated with a shorter TTNT [hazard ratio (HR) 3.309; p < 0.001]. Patients who 
      were treated with ICIs and chemotherapy combination were associated with a longer 
      TTNT (HR 0.389; p = 0.003). In addition, minor EGFR mutation was associated with 
      a long TTNT (HR 0.450; p = 0.046). CONCLUSION: ICIs were administered to only 22% 
      of patients with EGFR-mutated lung cancer, and they had shorter TTNT of EGFR-TKI 
      compared to other patients. ICI treatment should be avoided in EGFR mutated lung 
      cancer with poor PS but can be considered for lung cancer with EGFR minor 
      mutations. Pathological biomarker to predict long-term responders to ICI are 
      needed.
CI  - (c) 2024. The Author(s).
FAU - Kuribayashi, Tadahiro
AU  - Kuribayashi T
AD  - Department of Hematology, Oncology and Respiratory Medicine, Okayama University 
      Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 
      Japan.
FAU - Ohashi, Kadoaki
AU  - Ohashi K
AD  - Department of Allergy and Respiratory Medicine, Okayama University Hospital, 
      Okayama, Japan. kohashi@cc.okayama-u.ac.jp.
FAU - Nishii, Kazuya
AU  - Nishii K
AD  - Department of Hematology, Oncology and Respiratory Medicine, Okayama University 
      Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 
      Japan.
FAU - Ninomiya, Kiichiro
AU  - Ninomiya K
AD  - Department of Allergy and Respiratory Medicine, Okayama University Hospital, 
      Okayama, Japan.
FAU - Tsubata, Yukari
AU  - Tsubata Y
AD  - Department of Internal Medicine, Division of Medical Oncology and Respiratory 
      Medicine, Faculty of Medicine, Shimane University, Izumo, Japan.
FAU - Ishikawa, Nobuhisa
AU  - Ishikawa N
AD  - Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, 
      Japan.
FAU - Kodani, Masahiro
AU  - Kodani M
AD  - Division of Respiratory Medicine and Rheumatology, Department of 
      Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 
      Yonago, Japan.
FAU - Kanaji, Nobuhiro
AU  - Kanaji N
AD  - Department of Internal Medicine, Division of Hematology, Rheumatology, and 
      Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kagawa, 
      Japan.
FAU - Yamasaki, Masahiro
AU  - Yamasaki M
AD  - Department of Respiratory Medicine, Hiroshima Red Cross Hospital and Atomic-Bomb 
      Survivors Hospital, Hiroshima, Japan.
FAU - Fujitaka, Kazunori
AU  - Fujitaka K
AD  - Department of Molecular and Internal Medicine, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Kuyama, Shoichi
AU  - Kuyama S
AD  - Department of Respiratory Medicine, National Hospital Organization Iwakuni 
      Clinical Center, Iwakuni, Japan.
FAU - Takigawa, Nagio
AU  - Takigawa N
AD  - Department of Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
FAU - Fujimoto, Nobukazu
AU  - Fujimoto N
AD  - Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
FAU - Kubota, Tetsuya
AU  - Kubota T
AD  - Department of Respiratory Medicine and Allergology, Kochi University Hospital, 
      Kochi, Japan.
FAU - Inoue, Masaaki
AU  - Inoue M
AD  - Department of Chest Surgery, Shimonoseki City Hospital, Shimonoseki, Japan.
FAU - Fujiwara, Keiichi
AU  - Fujiwara K
AD  - Department of Respiratory Medicine, NHO Okayama Medical Center, Okayama, Japan.
FAU - Harita, Shingo
AU  - Harita S
AD  - Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, 
      Japan.
FAU - Takata, Ichiro
AU  - Takata I
AD  - Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
FAU - Takada, Kenji
AU  - Takada K
AD  - Department of Hematology, Oncology and Respiratory Medicine, Okayama University 
      Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 
      Japan.
FAU - Okawa, Sachi
AU  - Okawa S
AD  - Department of Hematology, Oncology and Respiratory Medicine, Okayama University 
      Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 
      Japan.
FAU - Kiura, Katsuyuki
AU  - Kiura K
AD  - Department of Allergy and Respiratory Medicine, Okayama University Hospital, 
      Okayama, Japan.
AD  - Internal Medicine, Kajiki Hospital, Okayama, Japan.
FAU - Hotta, Katsuyuki
AU  - Hotta K
AD  - Department of Allergy and Respiratory Medicine, Okayama University Hospital, 
      Okayama, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20240212
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (EGFR protein, human)
SB  - IM
MH  - Humans
MH  - Male
MH  - Aged
MH  - Female
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - ErbB Receptors/genetics
MH  - Mutation
MH  - Lung/pathology
PMC - PMC10861387
OTO - NOTNLM
OT  - EGFR
OT  - EGFR-TKI
OT  - Immune checkpoint inhibitors
OT  - Lung cancer
OT  - Performance status
COIS- Dr. Ohashi has received honoraria from Eli Lilly Japan K.K., Novartis Pharma 
      K.K., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Kyowa Kirin Co., Ltd., 
      and Novartis Pharma K.K; grants from Nippon Boehringer Ingelheim Co., Ltd., 
      Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co. Ltd., 
      Amgen K.K., and Novartis Pharma K.K; and receipt of research reagents from 
      Genentech, Inc. and Novartis Pharma K.K. outside the submitted work. Dr. Ninomiya 
      has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., 
      Ltd., Kyowa Kirin Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. 
      Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., MSD K.K., Ono 
      Pharmaceutical CO., LTD., Takeda Pharmaceutical CO., LTD., Pfizer Japan Inc., 
      Bristol Myers Squibb K.K., Elekta K.K., Janssen Pharmaceutical K.K., and Daiichi 
      Sankyo Co. Ltd. outside the submitted work. Dr. Tsubata has received honoraria 
      from Daiichi Sankyo Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., 
      Kyowa Kirin Co., Ltd, TAIHO PHARMACEUTICAL CO., LTD., and Bristol Myers Squibb 
      K.K.; and subsidies or donations from Pfizer Health Research Foundation outside 
      the submitted work. Dr. Ishikawa has received honoraria from AstraZeneca K.K. and 
      Nippon Boehringer-Ingelheim Co., Ltd. outside the submitted work. Dr. Kodani has 
      received AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Chugai 
      Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical CO., LTD., 
      Pfizer Japan Inc., TAIHO PHARMACEUTICAL CO., LTD., and Takeda Pharmaceutical CO., 
      LTD. outside the submitted work. Dr. Kuyama has received honoraria from Chugai 
      Pharmaceutical Co. Ltd., Bristol Myers Squibb K.K., Nippon Boehringer Ingelheim 
      Co., Ltd., AstraZeneca K.K., Pfizer Japan Inc., Eli Lilly Japan K.K., MSD K.K., 
      TAIHO PHARMACEUTICAL CO., LTD., Sanofi K.K., Kyowa Kirin Co., Ltd., Hisamitsu 
      Pharmaceutical Co., Inc., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., and 
      Novartis Pharma K.K. outside the submitted work. Dr. Takigawa has received grants 
      and personal fees from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., 
      TAIHO PHARMACEUTICAL CO., LTD., Nippon Boehringer-Ingelheim Co., Ltd., and; 
      grants from Kyowa Hakko Kirin Co., Ltd., Nippon Kayaku Co. Ltd., and Takeda 
      Pharmaceutical Co. Ltd.; and personal fees from AstraZeneca K.K., Pfizer Japan 
      Inc., Merck Japan, MSD K.K., Ono Pharmaceutical Co. Ltd. and Bristol Myers Squibb 
      K.K. outside the submitted work. Dr. Fujimoto received honoraria from Ono 
      Pharmaceutical Co. Ltd., AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., 
      and Nippon Kayaku Co., Ltd. outside the submitted work. Dr. Fujiwara has received 
      honoraria from MSD K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Sanofi 
      K.K., and Eli Lilly Japan K.K. outside the submitted work. Dr. Kiura has received 
      honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Merk 
      Biopharma, TAIHO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co. Ltd., Takeda 
      Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Pfizer Japan Inc. Bristol Myers 
      Squibb K.K., NipponKayaku Co., Ltd., Ono Pharmaceutical Co. Ltd., and MSD K.K.; 
      research fund from Nippon Boehringer-Ingelheim Co., Ltd., Ono Pharmaceutical Co. 
      Ltd., Novartis Pharma K.K., Takeda Pharmaceutical CO., LTD., Teijin pharma Ltd., 
      Kyorin Pharmaceutical Co., Ltd., Shionogi Pharma Co., Ltd., Nippon Kayaku Co., 
      Ltd., TAIHO PHARMACEUTICAL CO., LTD., and Chugai Pharmaceutical; and consulting 
      fees from Nippon Kayaku Co., Ltd., and Nipro Corp. outside the submitted work. 
      Dr. Hotta has received honoraria from Pfizer Japan Inc., AstraZeneca K.K., Chugai 
      Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Takeda Pharmaceutical CO., LTD., 
      MSD K.K., Bristol Myers Squibb K.K., Ono Pharmaceutical Co. Ltd., Nippon 
      Boehringer-Ingelheim Co., Ltd., and NipponKayaku Co., Ltd.; and research fund 
      from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan 
      K.K., Bristol Myers Squibb K.K., and Abbvie Inc. outside the submitted work.
EDAT- 2024/02/13 00:42
MHDA- 2024/02/13 06:44
PMCR- 2024/02/12
CRDT- 2024/02/12 23:33
PHST- 2023/11/22 00:00 [received]
PHST- 2024/01/09 00:00 [accepted]
PHST- 2024/02/13 06:44 [medline]
PHST- 2024/02/13 00:42 [pubmed]
PHST- 2024/02/12 23:33 [entrez]
PHST- 2024/02/12 00:00 [pmc-release]
AID - 10.1007/s00432-024-05618-4 [pii]
AID - 5618 [pii]
AID - 10.1007/s00432-024-05618-4 [doi]
PST - epublish
SO  - J Cancer Res Clin Oncol. 2024 Feb 12;150(2):89. doi: 10.1007/s00432-024-05618-4.